---
aliases: [ROG, Roche Holding]
---
#actor #pharma #diagnostics #switzerland #public

**Roche** — Swiss pharma + diagnostics. Oncology, immunology. Owns Genentech. ~$65B revenue.

---

## Why Roche matters

| Metric | Value |
|--------|-------|
| Ticker | ROG.SW (Swiss) |
| Market cap | ~$250B |
| Revenue | ~$65B |
| HQ | Basel, [[Switzerland]] |
| Structure | Pharma + Diagnostics |

---

## Business segments

| Segment | Revenue | Focus |
|---------|---------|-------|
| **Pharmaceuticals** | ~$45B | Oncology, immunology |
| **Diagnostics** | ~$15B | Lab testing, molecular |

---

## Key drugs

| Drug | Indication | Status |
|------|------------|--------|
| **Ocrevus** | Multiple sclerosis | Blockbuster |
| **Tecentriq** | Cancer (PD-L1) | Growing |
| **Hemlibra** | Hemophilia | Growing |
| **Perjeta** | Breast cancer | Mature |
| **Herceptin** | Breast cancer | Biosimilar pressure |
| **Avastin** | Multiple cancers | Biosimilar pressure |

---

## Genentech

| Detail | Value |
|--------|-------|
| Acquired | 2009 |
| Role | US pharma operations |
| Innovation | Biotech heritage |
| Location | South San Francisco |

---

## Diagnostics business

| Segment | Focus |
|---------|-------|
| Core Lab | Hospital testing |
| Molecular | PCR, sequencing |
| Tissue | Pathology |
| Diabetes Care | Blood glucose |
| Point of Care | Rapid testing |

**Advantage:** Pharma + diagnostics integration.

---

## Investment case

**Bull:**
- Ocrevus MS dominance
- Diagnostics diversification
- Strong pipeline
- Genentech innovation engine
- Swiss stability

**Bear:**
- Biosimilar erosion (Herceptin, Avastin)
- Oncology competition intense
- Currency headwinds (CHF)
- Premium valuation
- Slow growth profile

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | ROG.SW |
| Revenue | ~$65B |
| Segments | Pharma + Diagnostics |
| Key drug | Ocrevus |

---

## Related

- [[Biopharma]] — sector
- [[AstraZeneca]] — oncology competitor
- [[Novartis]] — Swiss peer
- [[Illumina]] — diagnostics ecosystem

---

## Sources

- Company filings

*Created 2026-01-09*
